Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.46 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylhydrazine SCHEMBL3667817 | 0.86 | GRM5 (0.60) | GRM5CYP11B2CYP11B1RPS6KA5BRD4 | |
| Ammonia Solution, Strong SCHEMBL3664527 | 0.81 | GRM5 (0.58) | GRM5CYP11B1KDM4ELMNA | |
| SCHEMBL3632412 | 0.75 | GRM5 (0.79) | GRM5CYP11B2CYP11B1BRD4 | |
| SCHEMBL3633416 | 0.75 | GRM5 (0.72) | GRM5CYP11B2CYP11B1BRD4 | |
| SCHEMBL3632240 | 0.74 | GRM5 (0.86) | GRM5CYP11B2CYP11B1 | |
| Methylhydrazine SCHEMBL3670926 | 0.74 | GRM5 (0.68) | GRM5CYP11B1KDM4ELMNA | |
| SCHEMBL3633693 | 0.74 | GRM5 (0.69) | GRM5CYP11B2CYP11B1BRD4KDM4E | |
| SCHEMBL3633531 | 0.73 | MAPT (0.53) | GRM5CYP11B2CYP11B1RPS6KA5BRD4 | |
| SCHEMBL3635470 | 0.72 | GRM5 (0.58) | GRM5CYP11B2CYP11B1BRD4KDM4E | |
| SCHEMBL3634343 | 0.72 | GRM5 (0.67) | GRM5CYP11B2CYP11B1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | GRM5 4545/4885CYP11B2 38/4885CYP11B1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.